Compare Stocks: ZLDPF, SBMFF, EXEL, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.70	$49.26 ▼ $70.98	$12.64B	0.24	2.32 million shs	1.10 million shs
EXEL Exelixis	$54.45 -1.5%	$54.57	$33.76 ▼ $57.57	$13.69B	0.44	2.68 million shs	1.49 million shs
SBMFF Sino Biopharmaceutical	$0.75	$0.64	$0.59 ▼ $1.24	$14.08B	0.68	1,787 shs	N/A
ZLDPF Zealand Pharma A/S	$49.29	$46.90	$35.93 ▼ $83.12	$3.53B	0.88	461 shs	2 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.95%	-3.04%	+5.38%	+12.88%	+10.25%
EXEL Exelixis	-1.47%	+0.68%	-1.47%	+7.86%	+41.39%
SBMFF Sino Biopharmaceutical	0.00%	0.00%	+17.80%	+18.53%	-24.13%
ZLDPF Zealand Pharma A/S	0.00%	-2.43%	+5.93%	+1.12%	-25.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.70	$49.26 ▼ $70.98	$12.64B	0.24	2.32 million shs	1.10 million shs
EXEL Exelixis	$54.45 -1.5%	$54.57	$33.76 ▼ $57.57	$13.69B	0.44	2.68 million shs	1.49 million shs
SBMFF Sino Biopharmaceutical	$0.75	$0.64	$0.59 ▼ $1.24	$14.08B	0.68	1,787 shs	N/A
ZLDPF Zealand Pharma A/S	$49.29	$46.90	$35.93 ▼ $83.12	$3.53B	0.88	461 shs	2 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.95%	-3.04%	+5.38%	+12.88%	+10.25%
EXEL Exelixis	-1.47%	+0.68%	-1.47%	+7.86%	+41.39%
SBMFF Sino Biopharmaceutical	0.00%	0.00%	+17.80%	+18.53%	-24.13%
ZLDPF Zealand Pharma A/S	0.00%	-2.43%	+5.93%	+1.12%	-25.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.79	37.30% Upside
EXEL Exelixis	2.30	Hold	$50.07	-8.05% Downside
SBMFF Sino Biopharmaceutical	0.00	N/A	N/A	N/A
ZLDPF Zealand Pharma A/S	2.20	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZLDPF, SBMFF, EXEL, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/13/2026	ZLDPF Zealand Pharma A/S	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/13/2026	ZLDPF Zealand Pharma A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.89	$2.83 per share	22.88	$32.66 per share	1.98
EXEL Exelixis	$2.32B	5.82	$2.98 per share	18.25	$7.44 per share	7.32
SBMFF Sino Biopharmaceutical	$4.02B	3.51	$0.02 per share	32.11	$0.32 per share	2.35
ZLDPF Zealand Pharma A/S	$1.40B	2.53	$13.81 per share	3.57	$31.61 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	174.78	11.98	0.47	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.12	14.68	1.64	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
SBMFF Sino Biopharmaceutical	$486.83M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZLDPF Zealand Pharma A/S	$977.29M	$6.03	8.17	35.46	N/A	58.86%	18.53%	17.14%	11/12/2026 (Estimated)

Latest ZLDPF, SBMFF, EXEL, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A
ZLDPF Zealand Pharma A/S	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A
ZLDPF Zealand Pharma A/S	0.02	37.17	37.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
SBMFF Sino Biopharmaceutical	N/A
ZLDPF Zealand Pharma A/S	N/A

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
SBMFF Sino Biopharmaceutical	N/A
ZLDPF Zealand Pharma A/S	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
SBMFF Sino Biopharmaceutical	24,379	18.76 billion	N/A	Not Optionable
ZLDPF Zealand Pharma A/S	340	71.53 million	N/A	Not Optionable

ZLDPF, SBMFF, EXEL, and BMRN Headlines

Recent News About These Companies

Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)

August 24, 2026 | markets.businessinsider.com

Zealand Pharma â Notification of holding of treasury shares

August 24, 2026 | markets.businessinsider.com

Zealand Pharma A/S

August 20, 2026 | barrons.com

Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)

August 17, 2026 | markets.businessinsider.com

Zealand Pharma A/S (OTCMKTS:ZLDPF) Lowered to "Strong Sell" Rating by Zacks Research

August 15, 2026 | marketbeat.com

Zealand Pharma A/S (ZLDPY) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates

August 13, 2026 | zacks.com

Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of "Hold" by Analysts

August 6, 2026 | marketbeat.com

Zealand Pharma A/S (ZLDPF) Projected to Post Earnings on Thursday

August 6, 2026 | marketbeat.com

Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Time to Buy?

August 3, 2026 | marketbeat.com

Zealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830

July 29, 2026 | tipranks.com

Zealand Pharma Advances First-in-Human Obesity Drug Trial With ZP6590

July 24, 2026 | tipranks.com

Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)

July 13, 2026 | markets.businessinsider.com

Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)

July 6, 2026 | markets.businessinsider.com

Total number of shares and voting rights in Zealand Pharma as of June 30, 2026

June 30, 2026 | markets.businessinsider.com

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

June 30, 2026 | markets.businessinsider.com

Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)

June 29, 2026 | markets.businessinsider.com

Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)

June 22, 2026 | markets.businessinsider.com

Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

June 19, 2026 | cnbc.com

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

June 15, 2026 | markets.businessinsider.com

Drugmakers race to find a place in the next wave of obesity drugs

June 13, 2026 | cnbc.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLDPF, SBMFF, EXEL, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$64.67 -0.62 (-0.95%)

As of 08/28/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$54.45 -0.81 (-1.47%)

As of 08/28/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Sino Biopharmaceutical OTCMKTS:SBMFF

$0.75 0.00 (0.00%)

As of 08/28/2026

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Zealand Pharma A/S OTCMKTS:ZLDPF

$49.29 0.00 (0.00%)

As of 08/28/2026

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZLDPF, SBMFF, EXEL, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZLDPF, SBMFF, EXEL, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZLDPF, SBMFF, EXEL, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLDPF, SBMFF, EXEL, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Sino Biopharmaceutical OTCMKTS:SBMFF

Zealand Pharma A/S OTCMKTS:ZLDPF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZLDPF, SBMFF, EXEL, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZLDPF, SBMFF, EXEL, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZLDPF, SBMFF, EXEL, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLDPF, SBMFF, EXEL, and BMRN Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Sino Biopharmaceutical OTCMKTS:SBMFF

Zealand Pharma A/S OTCMKTS:ZLDPF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools